Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study.

ABSTRACT:

Aims

Type 2 diabetes mellitus (T2DM) is commonly complicated by renal impairment. Polyethylene glycol loxenatide (PEX168) is a novel long-acting glucagon-like peptide-1 receptor agonist for T2DM. PEX168 pharmacokinetics was studied to identify requirements for dose-modification in T2DM complicated by renal impairment.

Methods

This was a single-centre, open-labelled, parallel-group, single-dose, phase I clinical trial of patients with mild and moderate renal impairment, and with or without T2DM. Age-, sex- and body mass index-matched subjects with normal renal function, and with or without T2DM were recruited as controls. Subjects received a single abdominal subcutaneous injection of PEX168 200 μg. Pharmacokinetic samples were taken at 0, 24, 48, 72, 96, 120, 144, 216, 312, 4

SUBMITTER: Wang J 

PROVIDER: S-EPMC6955414 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature